Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, ...

Ibrexafungerp, formerly known as SCY-078, is currently approved in the U.S. for the treatment of vulvovaginal candidiasis and is in late-stage of development for invasive candidiasis and other ...

For the few cases of invasive disease ... fungal infection during the post-treatment phase. The cases in the micafungin group (all Candida albicans) comprised 2 patients with candidemia ...

Vaginal infections, often termed "Infectious Vaginitis," are common concerns for women across the lifespan, with a higher ...

17 Clinical symptoms and notable growth of Candida ... potentially resulting in invasive candidiasis and various gastrointestinal disorders. Effective management strategies, including antifungal ...

SCY-247 inhibits glucan synthase, an enzyme involved in the formation of 1,3-beta-D-glucan, an essential component of the ...

a Comparison of adverse effects for all three echinocandins from their respective clinical trial for treatment of esophageal candidiasis where fluconazole was the comparator agent. Michele I.

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of ...